Amlodipine
- TRADE NAME: Amdepin; Amlodin; Amlogard; Amlopin; Amlor; Exforge (Novartis); Istin (Pfizer); Lotrel (Novartis); Norvas; Norvasc (Pfizer); Tekamlo (Novartis)
- INDICATIONS: Hypertension, angina
- CLASS: Antiarrhythmic class IV, Calcium channel blocker
- HALF-LIFE: 30–50 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Carbamazepine, Conivaptan, Epirubicin, Imatinib, Phenytoin, Primidone, Simvastatin, St John's Wort, Tadalafil, Telaprevir
PREGNANCY CATEGORY: C
Safety and effectiveness in pediatric patients <6 years of age have not been established.
Lotrel is amlodipine and benazepril; Tekamlo is amlodipine and aliskiren; Exforge is amlodipine and valsartan.
Please login to see the rest of this drug profile
SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
HEMATOLOGIC
OTIC
OCULAR
OTHER
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of amlodipine in the Informa Healthcare journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric